Does higher hs-CRP accompany greater pain and reduced physical function?

High-sensitivity C-reactive protein (hs-CRP) is a valid marker of systemic inflammatory signaling, but it is nonspecific. For a 64-year-old woman, an elevated result may coexist with greater pain and mobility limitations, while not establishing that inflammation is their direct cause.

Clinical and functional evidence

• In UK Biobank (n=415,567), higher CRP was associated with chronic regional pain after multivariable adjustment (odds ratios [ORs] 1.07–1.49 across pain types). NHANES found higher odds of chronic pain in the highest versus lowest CRP quartile (OR 1.32, 95% CI 1.10–1.58). These are modest, phenotype-dependent associations rather than diagnostic or predictive findings.
• Functional associations are more consistent in older populations. hs-CRP ≥3 mg/L was associated with faster gait-speed decline and incident mobility disability (adjusted hazard ratio 1.85, 95% CI 1.09–3.14); high CRP was also associated with poor physical function cross-sectionally (OR 2.67, 95% CI 1.43–4.99).

Mechanistic and interpretive context

• IL-6 and related inflammatory signaling induce hepatic CRP synthesis. Thus, hs-CRP reflects circulating inflammatory activity but cannot identify its source.
• Adiposity—particularly relevant because the BMI–CRP association is stronger in women—and current smoking can raise hs-CRP. Acute infection and recent trauma can cause substantial transient elevations. These factors can also relate independently to pain and functional status.

Practical interpretation

• A single elevated hs-CRP should not be taken as evidence that inflammation is causing pain or disability. It is best measured when clinically stable, without acute infection or recent trauma; two measurements about two weeks apart may be averaged. A value ≥10 mg/L warrants evaluation for acute or noncardiovascular inflammatory causes and repeat testing after recovery.

Bottom line

• Higher hs-CRP can accompany greater pain burden and reduced physical function, especially mobility vulnerability in older adults, but it is a contextual marker of systemic inflammation—not a causal explanation or standalone diagnosis.